For many women, motherhood is not a barrier but a catalyst. In conjunction with Mothers Day, four mothers share how raising a ...
Men’s Health spoke to Novo Nordisk's Thomas Kruse and Jesper Lau, the two chemists responsible for discovering ...
Infosys's client-specific headwinds and a shift to offshore delivery are weighing on near-term growth, despite positives. See ...
When Beetham Tower arrived on Deansgate twenty years ago, it meant business. The first residential skyscraper in Manchester, ...
Operator: Thank you for standing by, and welcome to Corcept Therapeutics First Quarter 2026 Earnings Conference Call.
Foreign Secretary Theresa Lazaro addressed the Manila Overseas Press Club April 30 (Thursday). She articulated eloquently the Philippines’ foreign policy. Excerpts from her speech: Diplomats and ...
Electroreduction offers a promising route for converting CO2 into value-added chemicals using renewable electricity. Among the possible products, formic acid is particularly attractive because it is ...
The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at ...
The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.
In a recent article, researchers from the University of Jyväskylä, Finland, emphasize the importance of multiscale modeling of catalysis in understanding and developing (electro)chemical processes.
May 7 (Reuters) - Angelini Pharma said on Thursday that it will acquire Catalyst Pharmaceuticals in a $4.1 billion deal, marking the Italian drugmaker's entry into the U.S. pharmaceutical market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results